Table 1.
The clinical features of all included patients and the correlations between clinical features and miR-216a expression
| Characteristics | Number of patients (n=87) |
miR-520g expression
|
P-value | |
|---|---|---|---|---|
| Low group (n=43) |
High group (n=44) |
|||
| Age | 0.500 | |||
| ≤50 | 29 | 16 | 13 | |
| >50 | 58 | 27 | 31 | |
| Ascites | 0.644 | |||
| ≤100 | 27 | 12 | 15 | |
| >100 | 60 | 31 | 29 | |
| Serum CA-125 | 0.713 | |||
| ≤35 | 8 | 3 | 5 | |
| >35 | 79 | 40 | 39 | |
| Tumor size | 0.101 | |||
| ≤3 cm | 61 | 34 | 27 | |
| >3 cm | 26 | 9 | 17 | |
| Lymph node metastasis | <0.01 | |||
| Negative | 49 | 34 | 15 | |
| Positive | 38 | 9 | 29 | |
| FIGO stage | 0.014 | |||
| I–II | 12 | 10 | 2 | |
| III–IV | 75 | 33 | 42 | |
Abbreviation: FIGO, Federation Internationale of Gynecologie and Obstetrigue.